260 related articles for article (PubMed ID: 36056951)
1. The predictive value of inflammatory biomarkers for major pathological response in non-small cell lung cancer patients receiving neoadjuvant chemoimmunotherapy and its association with the immune-related tumor microenvironment: a multi-center study.
Li C; Wu J; Jiang L; Zhang L; Huang J; Tian Y; Zhao Y; Liu X; Xia L; E H; Gao P; Hou L; Yang M; Ma M; Su C; Zhang H; Chen H; She Y; Xie D; Luo Q; Chen C
Cancer Immunol Immunother; 2023 Mar; 72(3):783-794. PubMed ID: 36056951
[TBL] [Abstract][Full Text] [Related]
2. Peripheral blood inflammatory biomarkers dynamics reflect treatment response and predict prognosis in non-small cell lung cancer patients with neoadjuvant immunotherapy.
Huai Q; Luo C; Song P; Bie F; Bai G; Li Y; Liu Y; Chen X; Zhou B; Sun X; Guo W; Gao S
Cancer Sci; 2023 Dec; 114(12):4484-4498. PubMed ID: 37731264
[TBL] [Abstract][Full Text] [Related]
3. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
[TBL] [Abstract][Full Text] [Related]
4. Prognostic impact of immune inflammation biomarkers in predicting survival and radiosensitivity in patients with non-small-cell lung cancer treated with chemoradiotherapy.
Delikgoz Soykut E; Kemal Y; Karacin C; Karaoglanoglu O; Kurt M; Aytac Arslan S
J Med Imaging Radiat Oncol; 2022 Feb; 66(1):146-157. PubMed ID: 34632714
[TBL] [Abstract][Full Text] [Related]
5. Tertiary lymphoid structures combined with biomarkers of inflammation are associated with the efficacy of neoadjuvant immunochemotherapy in resectable non-small cell lung cancer: A retrospective study.
Xu F; Zhu H; Xiong D; Wang K; Dong Y; Li L; Yuan S
Thorac Cancer; 2024 Jan; 15(2):172-181. PubMed ID: 38057283
[TBL] [Abstract][Full Text] [Related]
6. The predictive role of hematologic markers in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy: a retrospective cohort study.
Liu W; Ren S; Yang L; Xiao Y; Zeng C; Chen C; Wu F; Hu Y
Int J Surg; 2023 Nov; 109(11):3519-3526. PubMed ID: 37578441
[TBL] [Abstract][Full Text] [Related]
7. Maturation and abundance of tertiary lymphoid structures are associated with the efficacy of neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer.
Sun X; Liu W; Sun L; Mo H; Feng Y; Wu X; Li C; Chen C; Li J; Xin Y; Zhang Z; Wang C; Zhang B; Yue D
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 37011953
[TBL] [Abstract][Full Text] [Related]
8. Deep learning for predicting major pathological response to neoadjuvant chemoimmunotherapy in non-small cell lung cancer: A multicentre study.
She Y; He B; Wang F; Zhong Y; Wang T; Liu Z; Yang M; Yu B; Deng J; Sun X; Wu C; Hou L; Zhu Y; Yang Y; Hu H; Dong D; Chen C; Tian J
EBioMedicine; 2022 Dec; 86():104364. PubMed ID: 36395737
[TBL] [Abstract][Full Text] [Related]
9. Combined inflammatory parameters and tertiary lymphoid structure predict prognosis in patients with resectable non-small cell lung cancer treated with neoadjuvant chemoimmunotherapy.
Xu F; Zhu H; Dong Y; Li L; Liu N; Yuan S
Front Immunol; 2023; 14():1244256. PubMed ID: 38155965
[TBL] [Abstract][Full Text] [Related]
10. Delta-radiomics features for predicting the major pathological response to neoadjuvant chemoimmunotherapy in non-small cell lung cancer.
Han X; Wang M; Zheng Y; Wang N; Wu Y; Ding C; Jia X; Yang R; Geng M; Chen Z; Zhang S; Zhang K; Li Y; Liu J; Gu J; Liao Y; Fan J; Shi H
Eur Radiol; 2024 Apr; 34(4):2716-2726. PubMed ID: 37736804
[TBL] [Abstract][Full Text] [Related]
11. Combining serum inflammation indexes at baseline and post treatment could predict pathological efficacy to anti‑PD‑1 combined with neoadjuvant chemotherapy in esophageal squamous cell carcinoma.
Zhang X; Gari A; Li M; Chen J; Qu C; Zhang L; Chen J
J Transl Med; 2022 Feb; 20(1):61. PubMed ID: 35109887
[TBL] [Abstract][Full Text] [Related]
12. Effect of systemic inflammation biomarkers on overall survival after lung cancer radiotherapy: a single-center large-cohort study.
Abravan A; Salem A; Price G; Faivre-Finn C; van Herk M
Acta Oncol; 2022 Feb; 61(2):163-171. PubMed ID: 34979860
[TBL] [Abstract][Full Text] [Related]
13. COMPLETE BLOOD COUNT DERIVED INFLAMMATORY BIOMARKERS IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES.
Nanava N; Betaneli M; Giorgobiani G; Chikovani T; Janikashvili N
Georgian Med News; 2020 May; (302):39-44. PubMed ID: 32672687
[TBL] [Abstract][Full Text] [Related]
14. [CD103
Li BW; Ren SQ; Chen SL; Lan TJ; Wu F; Li JS
Zhonghua Kou Qiang Yi Xue Za Zhi; 2023 Dec; 58(12):1257-1264. PubMed ID: 38061868
[No Abstract] [Full Text] [Related]
15. Tumor immune microenvironment predicts the pathologic response of neoadjuvant chemoimmunotherapy in non-small-cell lung cancer.
Han R; Zhang Y; Wang T; Xiao H; Luo Z; Shen C; Li J; Zhao C; Li L; Zhu M; Du H; Tang H; Ma Z; Wang Y; He Y
Cancer Sci; 2023 Jun; 114(6):2569-2583. PubMed ID: 36880750
[TBL] [Abstract][Full Text] [Related]
16. Systemic immune-inflammation index predicting chemoradiation resistance and poor outcome in patients with stage III non-small cell lung cancer.
Tong YS; Tan J; Zhou XL; Song YQ; Song YJ
J Transl Med; 2017 Oct; 15(1):221. PubMed ID: 29089030
[TBL] [Abstract][Full Text] [Related]
17. The predictive value of systemic immune-inflammatory markers before and after treatment for pathological complete response in patients undergoing neoadjuvant therapy for breast cancer: a retrospective study of 1994 patients.
Wang H; Huang Z; Xu B; Zhang J; He P; Gao F; Zhang R; Huang X; Shan M
Clin Transl Oncol; 2024 Jun; 26(6):1467-1479. PubMed ID: 38190034
[TBL] [Abstract][Full Text] [Related]
18. Cancer-elicited inflammation attenuates response and outcome in tyrosine kinase inhibitor naive patients with advanced NSCLC.
Ying HQ; Liao YC; Luo YR; Xiong G; Huang Y; Nie RW; Xiong CF; Cheng XX
Pharmacol Res; 2021 Aug; 170():105734. PubMed ID: 34157424
[TBL] [Abstract][Full Text] [Related]
19. High systemic immune-inflammation index predicts poor prognosis in advanced lung adenocarcinoma patients treated with EGFR-TKIs.
Deng C; Zhang N; Wang Y; Jiang S; Lu M; Huang Y; Ma J; Hu C; Hou T
Medicine (Baltimore); 2019 Aug; 98(33):e16875. PubMed ID: 31415428
[TBL] [Abstract][Full Text] [Related]
20. Complete Blood Cell Count-Derived Inflammatory Biomarkers in Early-Stage Non-Small-Cell Lung Cancer.
Shoji F; Kozuma Y; Toyokawa G; Yamazaki K; Takeo S
Ann Thorac Cardiovasc Surg; 2020 Oct; 26(5):248-255. PubMed ID: 32074540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]